These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30831081)

  • 1. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).
    Mahalaxmi I; Devi SM; Kaavya J; Arul N; Balachandar V; Santhy KS
    Eur J Pharmacol; 2019 Jun; 852():51-57. PubMed ID: 30831081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stemness and chemoresistance are imparted to the OC cells through TGFβ1 driven EMT.
    Mitra T; Prasad P; Mukherjee P; Chaudhuri SR; Chatterji U; Roy SS
    J Cell Biochem; 2018 Jul; 119(7):5775-5787. PubMed ID: 29537103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin induces stemness in ovarian cancer.
    Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
    Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
    Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
    Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
    Kenda Suster N; Smrkolj S; Virant-Klun I
    J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers.
    Fatma H; Siddique HR; Maurya SK
    Epigenomics; 2021 Dec; 13(23):1885-1900. PubMed ID: 34693722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction.
    Alemohammad H; Asadzadeh Z; Motafakker Azad R; Hemmat N; Najafzadeh B; Vasefifar P; Najafi S; Baradaran B
    Life Sci; 2020 Nov; 260():118337. PubMed ID: 32841661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the
    Zhang W; Sui Y; Ni J; Yang T
    Int J Biol Sci; 2016; 12(11):1372-1381. PubMed ID: 27877089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the pluripotency and cancer stem cell-related marker NANOG in diagnosis and treatment of ovarian carcinoma.
    Kenda Suster N; Virant-Klun I; Frkovic Grazio S; Smrkolj S
    Eur J Gynaecol Oncol; 2016; 37(5):604-612. PubMed ID: 29786995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanog, as a key cancer stem cell marker in tumor progression.
    Vasefifar P; Motafakkerazad R; Maleki LA; Najafi S; Ghrobaninezhad F; Najafzadeh B; Alemohammad H; Amini M; Baghbanzadeh A; Baradaran B
    Gene; 2022 Jun; 827():146448. PubMed ID: 35337852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transcription factor NANOG in cancers--is eternal youth a curse?
    Wong OG; Cheung AN
    Expert Opin Ther Targets; 2016; 20(4):407-17. PubMed ID: 26634876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
    Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
    Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
    Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
    Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
    Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
    Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
    Ma X; Wang B; Wang X; Luo Y; Fan W
    PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
    Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
    Shan J; Shen J; Liu L; Xia F; Xu C; Duan G; Xu Y; Ma Q; Yang Z; Zhang Q; Ma L; Liu J; Xu S; Yan X; Bie P; Cui Y; Bian XW; Qian C
    Hepatology; 2012 Sep; 56(3):1004-14. PubMed ID: 22473773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.